PepGen Inc. (PEPG): Free Cash Flow
-$81.90M
Year ended 2025-12-31
-$69.46M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$81.90M | n/m | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | -$82.87M | n/m | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | -$71.60M | n/m | 2025-02-24, From 2023-01-01 |
| 2022-12-31 | -$63.02M | n/m | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | -$23.10M | n/a | 2023-03-23, From 2021-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| PepGen Inc. (PEPG) | 2025-12-31 | -$81.90M | n/m |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$171.34M | n/m |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | -$64.50M | n/m |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | -$54.54M | n/m |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | -$180.0K | n/m |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | -$16.62M | n/m |
| Apimeds Pharmaceuticals US, Inc. (APUS) | 2025-12-31 | -$8.98M | n/a |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | -$51.79M | n/m |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | -$67.85M | n/m |
Compare PEPG, GOSS, CRBP, CLYM side by side · Screen every company in Pharmaceutical Preparations ↗